BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced that it has been added to the Russell 2000® Index, a subset of the Russell 3000® Index, effective as of market closing on June 22, 2018, at the conclusion of the annual Russell US Index reconstitution.
"Being included in the Russell Index listings both increases visibility among the investment community and reflects the value ArQule creates for its shareholders," said Paolo Pucci, Chief Executive Officer of ArQule. "We are pleased to be included in the Indexes as we rapidly advance our pipeline of precision therapeutics for oncology and rare diseases.”
The Russell 3000® Index measures the performance of the largest 3,000 U.S. companies, which represents approximately 98% of the investable U.S. equity market. The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market. Russell Investments reconstitutes its indexes annually, determining membership for its equity indexes primarily by objective, rules-based market-capitalization rankings and style attributes. A list of companies included in these and other Russell Indexes can be found at www.ftse.com/analytics/factsheets.
About the Russell Indexes
Russell US Indexes are the leading US equity benchmarks for institutional investors. This broad range of US indexes allow investors to track current and historical market performance by specific size, investment style and other market characteristics. All Russell US Indexes are subsets of the Russell 3000® Index, which includes the well-known large cap Russell 1000® Index and small cap Russell 2000® Index. The Russell US Indexes are designed as the building blocks of a broad range of financial products, such as index tracking funds, derivatives and Exchange Traded Funds (ETFs), as well as being performance benchmarks. The reconstitution process, which occurs annually, is designed to capture and reflect market shifts that have occurred in the past year to ensure investors continue to have the most accurate US equity market benchmarks. For more information, please visit: http://www.ftserussell.com/index-series/index-spotlights/us-equity-indexes.
ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule’s mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. Our clinical-stage pipeline consists of five drug candidates, all of which are in targeted, biomarker-defined patient populations, making ArQule a leader among companies our size in precision medicine. ArQule’s pipeline includes: ARQ 531, an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant BTK, in Phase 1 for patients with B-cell malignancies refractory to other therapeutic options; Miransertib (ARQ 092), a selective inhibitor of the AKT serine/threonine kinase, in a phase 1/2 company-sponsored study for Overgrowth Diseases, in a Phase 1 study for ultra-rare Proteus syndrome conducted by the National Institutes of Health (NIH), and in Phase 1b in combination with the hormonal therapy, anastrozole, in patients with advanced endometrial cancer; ARQ 751 a next generation AKT inhibitor, in Phase 1 for patients with AKT1 and PI3K mutations; Derazantinib, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in a registrational trial for iCCA; and ARQ 761, a β-lapachone analog being evaluated as a promoter of NQO1-mediated programmed cancer cell necrosis, in Phase 1/2 in multiple oncology indications in partnership with the University of Texas Southwestern Medical Center. ArQule’s current discovery efforts are focused on the identification and development of novel kinase inhibitors, leveraging the Company’s proprietary library of compounds. You can follow us on Twitter and LinkedIn.